Literature DB >> 24854231

Pyriform sinus squamous cell carcinoma: oncological outcomes in good responders of induction chemotherapy-based larynx preservation protocols.

Zacharias Vourexakis1, Anne-Marie Le Ridant, Pavel Dulguerov, François Janot.   

Abstract

Induction chemotherapy-based larynx preservation protocols use chemotherapy to select exclusively patients with 'chemosensitive' tumors for a nonsurgical treatment with radiation therapy. This study on pyriform sinus squamous cell carcinoma (SCC) is interested in the oncological outcome of treatment based on radiation therapy when offered to patients with tumors responding to induction chemotherapy. This was a retrospective cohort study. The cohort included good responders to induction chemotherapy, subsequently treated with definite radiation therapy (with or without concomitant chemotherapy) for pyriform sinus SCC, in a tertiary referral cancer center. The primary endpoints were overall, laryngectomy-free and disease-free survival and the secondary endpoints were analysis of treatment failures and possibilities of salvage treatment. Forty-two patients fulfilled the inclusion criteria and were retained for analysis; 7% were stage II (3/42), 48% stage III (20/42) and 45% stage IV (19/42). At 1, 3 and 5 years, the overall survival was 95% (40/42), 74% (31/42), and 60% (SE ≈ 0.08), respectively. For the same intervals, the laryngectomy-free survival was 90% (38/42), 69% (29/42) and 50% (SE ≈ 0.08), respectively. The estimated 5-year disease-free survival was also 50%. Disease-free survival was significantly better for N0 patients. There was a 28% recurrence rate, mainly in the primary tumor site (9/11), with or without simultaneous nodal recurrence. Interestingly, more than one-third of all oncologic failures occurred beyond the first 3 years of follow-up. Salvage treatment was not possible or definitely inefficient in at least 2/3 of all recurrences. In candidates for larynx preservation for a pyriform sinus SCC, good response to induction chemotherapy followed by definite radiation therapy seems to be associated with a more favorable prognosis. Nevertheless, in case of locoregional recurrence the possibilities for efficient salvage treatment are limited.

Entities:  

Mesh:

Year:  2014        PMID: 24854231     DOI: 10.1007/s00405-014-3081-8

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  21 in total

1.  Advanced hypopharyngeal carcinoma treatment results according to treatment modalities.

Authors:  S Kim; H G Wu; D S Heo; K H Kim; M W Sung; C I Park
Journal:  Head Neck       Date:  2001-09       Impact factor: 3.147

Review 2.  Candidates for larynx preservation: the next step?

Authors:  Jean-Louis Lefebvre
Journal:  Oncologist       Date:  2010

3.  Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group.

Authors:  J L Lefebvre; D Chevalier; B Luboinski; A Kirkpatrick; L Collette; T Sahmoud
Journal:  J Natl Cancer Inst       Date:  1996-07-03       Impact factor: 13.506

4.  Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer.

Authors:  M J Zelefsky; D H Kraus; D G Pfister; A Raben; J P Shah; E W Strong; R H Spiro; G J Bosl; L B Harrison
Journal:  Head Neck       Date:  1996 Sep-Oct       Impact factor: 3.147

5.  Evaluation of overall tumor cellularity after neoadjuvant chemotherapy in patient with locally advanced hypopharyngeal cancer.

Authors:  Shun-ichi Chitose; Hideki Chijiwa; Akiteru Maeda; Hirohito Umeno; Tadashi Nakashima; Kensuke Kiyokawa; Naofumi Hayabuchi; Hiromasa Fujita
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-01-10       Impact factor: 2.503

6.  Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.

Authors:  M R Posner; C M Norris; L J Wirth; D M Shin; K J Cullen; E W Winquist; C R Blajman; E A Mickiewicz; G P Frenette; L F Plinar; R B Cohen; L M Steinbrenner; J M Freue; V A Gorbunova; S A Tjulandin; L E Raez; D R Adkins; R B Tishler; M R Roessner; R I Haddad
Journal:  Ann Oncol       Date:  2009-01-29       Impact factor: 32.976

7.  Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma.

Authors:  Jean-Michel Prades; Benjamin Lallemant; Renaud Garrel; Emile Reyt; Christian Righini; Thierry Schmitt; Nagib Remini; Lea Saban-Roche; Andrei P Timoshenko; Beatrice Trombert; Bernard Guerrier
Journal:  Acta Otolaryngol       Date:  2010       Impact factor: 1.494

8.  Prognostic factors for hypopharyngeal cancer: a univariate and multivariate study of 142 cases.

Authors:  Masato Mochiki; Masashi Sugasawa; Ken-Ichi Nibu; Masao Asai; Kazunari Nakao; Takahiro Asakage
Journal:  Acta Otolaryngol Suppl       Date:  2007-12

9.  Larynx preservation clinical trial design: key issues and recommendations--a consensus panel summary.

Authors:  Jean-Louis Lefebvre; K Kian Ang
Journal:  Head Neck       Date:  2009-04       Impact factor: 3.147

10.  Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.

Authors:  Yoann Pointreau; Pascal Garaud; Sophie Chapet; Christian Sire; Claude Tuchais; Jacques Tortochaux; Sandrine Faivre; Stephane Guerrif; Marc Alfonsi; Gilles Calais
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.